Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
87 hedge funds and large institutions have $637M invested in Adaptimmune Therapeutics in 2020 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 19 closing their positions.
60% more call options, than puts
Call options by funds: $1.23M | Put options by funds: $767K
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
10% more funds holding
Funds holding: 79 → 87 (+8)
1.26% less ownership
Funds ownership: 13.99% → 12.74% (-1.3%)
38% less capital invested
Capital invested by funds: $1.03B → $637M (-$393M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$27.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$19M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$17.8M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$10M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$48M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$40.5M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$23.3M |
| 4 |
RI
RTW Investments
New York
|
-$20.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$20.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MFS
101
Mirabella Financial Services
London,
United Kingdom
| – | -$198K | -24,804 | Closed |
|
|
KJHP
102
K.J. Harrison & Partners
Toronto,
Ontario, Canada
| – | -$160K | -20,000 | Closed |
|
103
Truist Financial
Charlotte,
North Carolina
| – | -$141K | -17,633 | Closed |
|
|
WCA
104
Windsor Creek Advisors
Bethel,
Vermont
| – | -$128K | -16,089 | Closed |
|
|
WI
105
WrapManager Inc
Mill Valley,
California
| – | -$125K | -15,660 | Closed |
|
106
Osaic Holdings
Scottsdale,
Arizona
| – | -$101K | -12,676 | Closed |
|
ADAP Hedge Fund Activity: Q4 2020 in Review
87 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2020, worth a combined $637M — down 38% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ADAP positions and 19 closed out — a net gain of 8 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $27.7M. The largest seller was RA Capital Management, cutting an estimated $48M.
- 87 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2020, up from 79 in Q3 2020.
- Funds reported $637M of Adaptimmune Therapeutics stock for Q4 2020, down 38% quarter-over-quarter.
- 27 funds opened new Adaptimmune Therapeutics positions in Q4 2020 and 19 closed out, a net change of +8 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $27.7M added.
- The largest Adaptimmune Therapeutics seller in Q4 2020 was RA Capital Management, an estimated $48M sold.
Based on aggregated 13F filings for Q4 2020.